cradle

Cradle Bio B.V.

Background

Cradle Bio B.V., operating as Cradle, is a Dutch–Swiss biotechnology company specializing in protein engineering through machine learning. Founded in 2021, Cradle is headquartered in Amsterdam, Netherlands, with an additional office in Zürich, Switzerland. The company's mission is to revolutionize the design and engineering of proteins by leveraging advanced AI technologies, aiming to enhance the development of pharmaceuticals, bio-based products, and sustainable materials. Cradle's vision is to simplify the complex process of designing cell-factories, enabling the production of a wide range of products, including fabrics, food, fuel, and medicines, through innovative tools and machine-learning models. This approach positions Cradle as a significant player in the biotechnology industry, particularly in the realm of AI-driven protein engineering.

Key Strategic Focus

Cradle's strategic focus centers on utilizing generative AI to design novel proteins with desired properties, such as stability and binding affinity. The company specializes in developing software platforms that apply machine learning techniques to predict and optimize protein sequences. By integrating AI with experimental data, Cradle aims to accelerate the development of therapeutic proteins, enzymes, antibodies, and other bio-based products. The primary markets targeted include pharmaceuticals, biotechnology, and sustainable materials, where efficient and innovative protein design is crucial.

Financials and Funding

Cradle has demonstrated strong financial growth through successive funding rounds:

• Seed Round (November 2022): Raised €5.5 million, led by Index Ventures.

• Series A (November 2023): Secured $24 million, also led by Index Ventures.

• Series B (November 2024): Raised $73 million, led by IVP.

These investments have been instrumental in expanding Cradle's technological capabilities, enhancing its AI-driven protein design platform, and supporting the growth of its in-house laboratory facilities.

Pipeline Development

Cradle's pipeline development focuses on the application of its AI platform to various protein engineering projects, including:

• Therapeutic Proteins: Designing proteins for medical applications, such as enzymes and antibodies.

• Sustainable Materials: Developing proteins for bio-based products and sustainable materials.

The company employs a lab-in-the-loop approach, integrating experimental data with AI predictions to refine protein designs iteratively. This methodology has significantly accelerated development timelines, with clients reporting up to a 90% reduction in experimental rounds.

Technological Platform and Innovation

Cradle's technological platform is distinguished by several innovative features:

• Proprietary Generative AI Models: Trained on extensive protein sequence data, these models predict amino acid sequences with desired properties.

• Lab-in-the-Loop Integration: Combines AI predictions with experimental data to iteratively refine protein designs.

• User-Friendly Interface: Designed for accessibility by scientists without specialized bioinformatics or machine learning expertise.

These innovations enable Cradle to accelerate protein design processes, reduce costs, and increase the success rate of R&D projects.

Leadership Team

Cradle's leadership team comprises individuals with diverse backgrounds in AI, software engineering, and synthetic biology:

• Stef van Grieken (CEO): Former leader at Google AI and X (Google's "moonshot factory").

• Jelle Prins (Co-Founder): Early employee at Uber, involved in app design.

• Elise de Reus (Co-Founder): Synthetic biologist heading partnerships and in-house lab development.

• Harmen van Rossum (Co-Founder): Leads the Amsterdam laboratory.

• Eli Bixby (Co-Founder): Former member of Google Brain.

This team's combined expertise drives Cradle's innovative approach to protein engineering.

Competitor Profile

• Market Insights and Dynamics: The biotechnology sector, particularly in AI-driven protein engineering, is experiencing rapid growth, with increasing demand for efficient and innovative solutions in drug discovery and sustainable materials.

• Competitor Analysis: Cradle faces competition from other biotech firms specializing in AI and protein engineering, such as Basecamp Research and Beyond Known Biology. These companies also leverage machine learning for protein design but may differ in their specific applications and technological approaches.

Strategic Collaborations and Partnerships

Cradle has established collaborations with leading pharmaceutical and biotechnology companies, including Johnson & Johnson Innovation, Novozymes, and Twist Bioscience. These partnerships enhance Cradle's market position and innovation capacity, facilitating the application of its AI-driven protein design platform across various industries.

Operational Insights

Cradle's strategic considerations include differentiating itself through its unique AI-driven approach, maintaining a user-friendly platform, and fostering strong industry partnerships. These factors contribute to its competitive advantages in the biotechnology sector.

Strategic Opportunities and Future Directions

Cradle's roadmap includes expanding its technological capabilities, enhancing its laboratory facilities, and broadening its client base across pharmaceuticals, biotechnology, and sustainable materials sectors. The company's strengths position it to achieve future objectives in revolutionizing protein engineering.

Contact Information

• Website: cradle.bio

• Social Media:

• LinkedIn: Cradle Bio

• Twitter: @CradleBio

• Facebook: Cradle Bio